Comparative Pharmacology
Head-to-head clinical analysis: DYNAPEN versus PENICILLIN G PROCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYNAPEN versus PENICILLIN G PROCAINE.
DYNAPEN vs PENICILLIN G PROCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dynapen (dicloxacillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
250-500 mg orally every 6 hours for skin and soft tissue infections; up to 500 mg every 6 hours for respiratory tract infections.
1.2 million to 2.4 million units intramuscularly once daily for most infections (e.g., uncomplicated pneumonia); for neurosyphilis, 2.4 million units intramuscularly once daily plus probenecid 500 mg orally four times daily for 10-14 days. Administer deep IM injection, not IV.
None Documented
None Documented
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria.
Terminal elimination half-life is approximately 0.5-1 hour in patients with normal renal function. Clinically, the prolonged absorption from the intramuscular depot results in sustained serum concentrations, with effective levels lasting 12-24 hours.
Renal: 60-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: <10%.
Primarily renal excretion via tubular secretion and glomerular filtration. Approximately 60-90% of a dose is excreted unchanged in urine within 24 hours. Biliary/fecal elimination is minor (<10%).
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic